1921
Volume 101, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The CYD-TDV vaccine is licensed in multiple endemic countries based on vaccine efficacy (VE) against symptomatic, virologically confirmed dengue demonstrated in two phase 3 trials (CYD14, 2- to 14-year-olds, Asia; CYD15, 9- to 16-year-olds, Latin America). 50% plaque reduction neutralization test (PRNT) titers at baseline and month 13 (post-vaccination) were associated with VE and may enable bridging VE to adults. Two phase 2 trials of CYD-TDV measured baseline and month 13 PRNT titers: CYD22 (9- to 45-year-olds, Vietnam) and CYD47 (18- to 45-year-olds, India). 50% plaque reduction neutralization test distributions were compared between age cohorts, and four versions of an epidemiological bridging method were used to estimate VE against any serotype (dengue virus [DENV]-Any) and against each serotype over 25 months post first vaccination in a hypothetical CYD14 + CYD15 18- to 45-year-old cohort (bridging population 1) and in the actual CYD47 18- to 45-year-old cohort (bridging population 2). Baseline and month 13 geometric mean PRNT titers to each serotype were significantly greater in 18- to 45-year-olds than 9- to 16-year-olds for all comparisons. The four methods estimated VE against DENV-Any at 75.3–86.0% (95% CIs spanning 52.5–100%) for bridging population 1 and 68.4–77.5% (95% CIs spanning 42.3–88.5%) for bridging population 2. The vaccine efficacy against serotype 1, 2, 3, and 4 was estimated at 56.9–76.9%, 68.3–85.8%, 91.4–95.0%, and 93.2–100% (bridging population 1) and 44.5–66.9%, 53.2–69.2%, 79.8–92.0%, and 90.6–95.0% (bridging population 2), respectively; thus, CYD-TDV would likely confer improved efficacy in adults than 9- to 16-year-olds. Using the same methods, we predicted VE against hospitalized DENV-Any over 72 months of follow-up, with estimates 59.1–73.5% (95% CIs spanning 40.9–92.2%) for bridging population 1 and 50.9–65.9% (95% CIs spanning 38.1–82.1%) for bridging population 2.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0534
2019-05-20
2020-09-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/101/1/tpmd180534.html?itemId=/content/journals/10.4269/ajtmh.18-0534&mimeType=html&fmt=ahah

References

  1. Murray NE, Quam MB, Wilder-Smith A, 2013. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol 5: 299309.
    [Google Scholar]
  2. World Health Organization, 2012. World Health Organization (WHO) Global Strategy for Dengue Prevention and Control, 2012–2020. Geneva, Switzerland: WHO Press.
    [Google Scholar]
  3. Bhatt S et al., 2013. The global distribution and burden of dengue. Nature 496: 504507.
    [Google Scholar]
  4. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI, 2012. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 6: e1760.
    [Google Scholar]
  5. Thai KT, Binh TQ, Giao PT, Phuong HL, Hung le Q, Van Nam N, Nga TT, Groen J, Nagelkerke N, de Vries PJ, 2005. Seroprevalence of dengue antibodies, annual incidence and risk factors among children in southern Vietnam. Trop Med Int Health 10: 379386.
    [Google Scholar]
  6. Low SL, Lam S, Wong WY, Teo D, Ng LC, Tan LK, 2015. Dengue seroprevalence of healthy adults in Singapore: serosurvey among blood donors, 2009. Am J Trop Med Hyg 93: 4045.
    [Google Scholar]
  7. Chew CH et al., 2016. Rural-urban comparisons of dengue seroprevalence in Malaysia. BMC Public Health 16: 824.
    [Google Scholar]
  8. Rodriguez-Barraquer I, Buathong R, Iamsirithaworn S, Nisalak A, Lessler J, Jarman RG, Gibbons RV, Cummings DA, 2014. Revisiting Rayong: shifting seroprofiles of dengue in Thailand and their implications for transmission and control. Am J Epidemiol 179: 353360.
    [Google Scholar]
  9. Carabali M, Hernandez LM, Arauz MJ, Villar LA, Ridde V, 2015. Why are people with dengue dying? A scoping review of determinants for dengue mortality. BMC Infect Dis 15: 301.
    [Google Scholar]
  10. Sam SS, Omar SF, Teoh BT, Abd-Jamil J, AbuBakar S, 2013. Review of dengue hemorrhagic fever fatal cases seen among adults: a retrospective study. PLoS Negl Trop Dis 7: e2194.
    [Google Scholar]
  11. Moraes GH, de Fatima Duarte E, Duarte EC, 2013. Determinants of mortality from severe dengue in Brazil: a population-based case-control study. Am J Trop Med Hyg 88: 670676.
    [Google Scholar]
  12. Egger JR, Coleman PG, 2007. Age and clinical dengue illness. Emerg Infect Dis 13: 924925.
    [Google Scholar]
  13. Thai KT, Nishiura H, Hoang PL, Tran NT, Phan GT, Le HQ, Tran BQ, Nguyen NV, de Vries PJ, 2011. Age-specificity of clinical dengue during primary and secondary infections. PLoS Negl Trop Dis 5: e1180.
    [Google Scholar]
  14. Guy B, Lang J, Saville M, Jackson N, 2016. Vaccination against dengue: challenges and current developments. Annu Rev Med 67: 387404.
    [Google Scholar]
  15. Villar L et al., 2015. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372: 113123.
    [Google Scholar]
  16. Capeding MR et al., 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384: 13581365.
    [Google Scholar]
  17. Juraska M et al., 2018. Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. Proc Natl Acad Sci USA 115: E8378E8387.
    [Google Scholar]
  18. Moodie Z et al., 2018. Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America. J Infect Dis 217: 742753.
    [Google Scholar]
  19. Hadinegoro SR et al., 2015. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373: 11951206.
    [Google Scholar]
  20. Sridhar S et al., 2018. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med 379: 327340.
    [Google Scholar]
  21. Mizumoto K, Ejima K, Yamamoto T, Nishiura H, 2014. On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling. J Vector Borne Dis 51: 153164.
    [Google Scholar]
  22. Pancharoen C, Mekmullica J, Thisyakorn U, 2001. Primary dengue infection: what are the clinical distinctions from secondary infection? Southeast Asian J Trop Med Public Health 32: 476480.
    [Google Scholar]
  23. Endy TP, Yoon IK, Mammen MP, 2010. Prospective cohort studies of dengue viral transmission and severity of disease. Curr Top Microbiol Immunol 338: 113.
    [Google Scholar]
  24. Guy B, Jackson N, 2016. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 14: 4554.
    [Google Scholar]
  25. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E, 2017. Antibody-dependent enhancement of severe dengue disease in humans. Science 358: 929932.
    [Google Scholar]
  26. Salje H et al., 2018. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature 557: 719723.
    [Google Scholar]
  27. Ferguson NM, Rodriguez-Barraquer I, Dorigatti I, Mier-Y-Teran-Romero L, Laydon DJ, Cummings DA, 2016. Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment. Science 353: 10331036.
    [Google Scholar]
  28. World Health Organization, 2018. Revised SAGE Recommendation on Use of Dengue Vaccine. Available at: http://www.who.int/immunization/diseases/dengue/revised_SAGE_recommendations_dengue_vaccines_apr2018/en/. Accessed April 19, 2018.
    [Google Scholar]
  29. Tran N, Luong C, Vu T, Forrat R, Lang J, Vu Q, Bouckenooghe A, Wartel T, 2012. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin 3: 162.
    [Google Scholar]
  30. Dubey AP, Agarkhedkar S, Chhatwal J, Narayan A, Ganguly S, Wartel TA, Bouckenooghe A, Menezes J, 2016. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: a randomized, observer-blind, placebo-controlled phase II trial. Hum Vaccin Immunother 12: 512518.
    [Google Scholar]
  31. Gilbert PB, Huang Y, 2016. Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy. Epidemiol Methods 5: 93112.
    [Google Scholar]
  32. Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW, 2013. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 88: 962970.
    [Google Scholar]
  33. Juraska M, Huang Y, Gilbert PB, 2018. Inference on treatment effect modification by biomarker response in a three-phase sampling design. Biostatistics. Available at: https://doi.org/10.1093/biostatistics/kxy074 [Epub ahead of print].
    [Google Scholar]
  34. Plotkin SA, Gilbert PB, 2012. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 54: 16151617.
    [Google Scholar]
  35. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG, 2007. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 196: 13041312.
    [Google Scholar]
  36. Gilbert PB, Gabriel EE, Miao X, Li X, Su SC, Parrino J, Chan IS, 2014. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis 210: 15731581.
    [Google Scholar]
  37. Huang Y, Gilbert PB, Janes H, 2012. Assessing treatment-selection markers using a potential outcomes framework. Biometrics 68: 687696.
    [Google Scholar]
  38. Clapham HE et al., 2016. Dengue virus (DENV) neutralizing antibody kinetics in children after symptomatic primary and postprimary DENV infection. J Infect Dis 213: 14281435.
    [Google Scholar]
  39. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E, 2016. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci USA 113: 728733.
    [Google Scholar]
  40. Sabchareon A et al., 2012. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 15591567.
    [Google Scholar]
  41. Plotkin SA, 2010. Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 10551065.
    [Google Scholar]
  42. Harenberg A et al., 2013. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother 9: 23172325.
    [Google Scholar]
  43. Elong Ngono A, Chen HW, Tang WW, Joo Y, King K, Weiskopf D, Sidney J, Sette A, Shresta S, 2016. Protective role of cross-reactive CD8 T cells against dengue virus infection. EBioMedicine 13: 284293.
    [Google Scholar]
  44. Weiskopf D, Bangs DJ, Sidney J, Kolla RV, De Silva AD, de Silva AM, Crotty S, Peters B, Sette A, 2015. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc Natl Acad Sci USA 112: E4256E4263.
    [Google Scholar]
  45. Mathew A, Townsley E, Ennis FA, 2014. Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol 9: 411425.
    [Google Scholar]
  46. Dayan GH, Galan-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J, 2014. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico. Hum Vaccin Immunother 10: 28532863.
    [Google Scholar]
  47. Hanna-Wakim R, Yasukawa LL, Sung P, Fang M, Sullivan B, Rinki M, DeHovitz R, Arvin AM, Gans HA, 2009. Age-related increase in the frequency of CD4(+) T cells that produce interferon-gamma in response to staphylococcal enterotoxin B during childhood. J Infect Dis 200: 19211927.
    [Google Scholar]
  48. L’Azou M et al., 2018. Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014). Trans R Soc Trop Med Hyg 112: 158168.
    [Google Scholar]
  49. Simon AK, Hollander GA, McMichael A, 2015. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci 282: 20143085.
    [Google Scholar]
  50. Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB, 2002. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 6: 118124.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0534
Loading
/content/journals/10.4269/ajtmh.18-0534
Loading

Data & Media loading...

Supplemental material

  • Received : 27 Jun 2018
  • Accepted : 30 Mar 2019
  • Published online : 20 May 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error